Inflazome

Inflazome is a biotechnology company leading the development of oral drugs aimed at addressing unmet clinical needs in inflammatory diseases by targeting the inflammasome. From Parkinson's and Alzheimer's to asthma, inflammatory bowel disease, chronic kidney disease, cardiovascular disease, arthritis, and NASH, the inflammasome is believed to contribute to many chronic inflammatory conditions. Inflazome has a range of orally available small-molecule NLRP3 inhibitors, with the lead molecule having successfully completed Phase I clinical trials along with several high-potential early-stage programs.